Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Zhan Yao(Loxo Oncology at Lilly (United States)), Li Ren Kong(Nanyang Technological University), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Ricardo J. Ramirez(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Helen Won(Unknown), Barry S. Taylor(Memorial Sloan Kettering Cancer Center), Neal Rosen(Memorial Sloan Kettering Cancer Center), Cailian Liu(Memorial Sloan Kettering Cancer Center), Christine A. Pratilas(Johns Hopkins University), Antoni Ribas(University of California, Los Angeles), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Aphrothiti J. Hanrahan(Memorial Sloan Kettering Cancer Center), Taha Merghoub(Cornell University), Alexis M. Jones(Memorial Sloan Kettering Cancer Center), Shakuntala Tiwari(Memorial Sloan Kettering Cancer Center)
Cited by 310
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k